Keynote Speaker (appear in sessions order)
Graduated from Tokyo Univ. studied biochemistry. Involved in the research and development of EPO, G-CSF, TPO, α-galactosyl ceramaide, stem cell mobilization, PBSCT, re-duced intensity HSCT, DC therapy, Exosome therapy, re-generative therapy using CD133+/CD34+ cells as well as cell separation. Immune cell therapy using NK cells, NKT cells and T-cells. Worked for ISCT since 1991, involved in the establishment of ACTO. During the development of EPO, established the CHO production system and regulato-ry standard in collaboration with regulatory agencies in USA, Europe, Japan, China, Korea and Taiwan. Worked for platelet production from iPSc at the Institute of Medical Science, Tokyo University.
Current role: Chairperson of ACTO, Editorial Board Mem-ber of Cytotherapy, R & D Director of Research Foundation for Community Medicine. Chair for the certified special committee for regenerative medicine.
Professor/Chair, Saga University
Professor Koichi Nakayama is a regenerative medicine and tissue engineering researcher at Saga University. He has established a method to fabricate transplantable, 3-D scaffold-free tissue. Koichi’s long-term goal is to manufacture living organs for transplantation based on a combination of robotic technology and biotechnology.
Research Director Exosome and Secreted Nano-vesicle (LSK Lab)
I graduated with a BSc (Hons in Biochemistry), National Uni-versity of Singapore, 1985 and a PhD (Molecular Biology), SUNY at Buffalo, 1992, and undertook postdoctoral training at Columbia University as a Cooley’s Anemia Foundation Research Fellow (1992-94) and Leukemia Society of Amer-ica Special Fellow (1994-96). From 1996, I led independent research groups at NUMI, NUS (National University of Sin-gapore) (1996-2001), Genome Institute of Singapore (2002-2007), Institute of Medical Biology (2007-2020) and Institute of Cell and Molecular Biology (2020-present). My research focus has always been on the elucidation of the underlying molecular and cellular mechanisms in diseases and devel-opment of therapies. Presently, my major research interests are in natural and synthetic nano-lipid vesicles, especially their synthesis and purification, biochemical and biophysical characterization, and diagnostic and therapeutic applica-tions. My two most notable scientific achievements are the discovery of stable eukaryotic mRNA decay intermediates in mammalian cells and the discovery of therapeutic MSC exo-somes. I discovered MSC exosomes in 2008. Following rig-orous interrogation of MSC exosome biology, my collabora-tors and I rationalized and demonstrated several world “firsts” in the efficacious use of MSC exosome efficacy against many diseases and injuries, development of scala-ble exosome production technologies, identification of key regulatory metrics in exosome drug release criteria and elu-cidate a disease-specific mechanism of action of MSC exo-some. For this work, I was recognized as a 2021 Highly Cited Researchers by the Clarivate Analytics Web of Sci-ence Group (Top 0.1% globally).
Director and Professor, Center for iPS Cell Research and Application (CiRA)
Jun Takahashi is a director and professor of the Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan. He graduated from the Kyoto University Faculty of Medicine in 1986 and thereafter started his career as a neurosurgeon at Kyoto University Hospital. After he earned his Ph.D. from the Kyoto University Graduate School of Medicine, he worked as a postdoctoral research fellow at the Salk Institute (Dr. Fred Gage), CA, U.S.A., where he started research work on neural stem cells. After returning to Kyoto University Hospital, he conducted functional neurosurgery including deep brain stimulation and also research work on stem cell therapy for Parkinson’s disease. In 2012, he became a full professor at CiRA, pursuing stem cell therapies for Parkinson’s disease patients. As a physician-scientist, he has laid the groundwork for the clinical application of iPS cells by developing effective differentiation protocols to dopaminergic neurons, selective sorting of the differentiated dopaminergic progenitor cells, and optimization of the host brain environment to maximize the survival and function of the transplanted cells in rodent and monkey brains. Based on these achievements, he started the world’s first clinical trial for Parkinson’s disease using iPS cells in 2018.
Prof of Hematology and Stem Cell Biology
Willem E. Fibbe MD, Ph.D. is professor of Hematology and Stem Cell Biology (em) at the Departments of Internal Medicine at the Leiden University Medical Centre (LUMC). He studied medicine at the Free University in Amsterdam.
He completed his PhD in 1988 (cum laude) and became Head of the Bone Marrow Transplantation Program in 1991. In 2005 he was appointed as head of the Department of Immunohematology and Blood Transfusion. In 2007 he was appointed Chairman Division IV of the LUMC. He has been a member of the Commission for Advanced Therapies (CAT) of the European Medicines Agency (EMA) and is an active member of the Central Committee for Research on Human Subjects in the Netherlands (CCMO). He has been a member of several advisory committees of the National Health Council and is the chairman of the Hematology Working Group of WHO-ICD11 and a member of WHO's Medical and Scientific Advisory Committee for ICD-11. He is a member of the Subcommittee on Precision Medicine of the American Society of Hematology (ASH) and chairs the Governance Committee of the European Hematology Association (EHA). He has been an Associate Editor of Blood and President of the EHA. In 2015 he co-founded the Leiden Regenerative Medicine Platform (LRMP) and since 2017 he is Chief Scientific Officer of Starfish Innovations. In 2018 he was awarded Knight in the Order of the Lion of the Netherlands.
Prof. Fibbe chaired the Regenerative Medicine Research Profile at LUMC and University of Leiden.
His primary research interest is in the field of hematopoietic stem cell biology and regenerative medicine, focusing on cellular tharapies, including mesenchymal stromal cells, tissue repair and cellular immunotherapies.
Don and Marilyn Anderson Professor, University of Wisconsin in Madison
Jacques Galipeau, M.D. FRCP(C) is the Don and Marilyn Anderson Professor of Oncology within the Department of Medicine and UW Carbone Comprehensive Cancer Center at the University of Wisconsin in Madison, and is Associate Dean for Therapeutics Development at the University of Wisconsin School of Medicine & Public Health. He is the director of the University of Wisconsin Advanced Cell Therapy Program whose mission is to develop personalized cell therapies for immune and malignant disorders and to promote and deploy first-in-human clinical trials of UW cell therapy innovations to improve outcomes for children and adults. Dr. Galipeau leads a research program in the study and use of mesenchymal stromal cells as an immunotherapy of catastrophic illnesses including cancer and immune disease. He has also developed the field of fusion engineered cytokines known as fusokines, as a novel pharmaceutical means of treating immune disorders and cancer. He is an internationally recognized expert in translational development of cellular pharmaceuticals and the sponsor of a series of FDA-sanctioned clinical trials examining the use of personalized cell therapies.
Dr. Galipeau is President of the ISCT (International Society for Cell Therapy) 2022-2024
Visiting Professor, Division of Immuno-Gene & Cell Therapy (Takara Bio) Senior Adviser, Center for Gene Therapy Research (CGTR) Jichi Medical University
Keiya Ozawa received his M.D. from University of Tokyo in 1977 and his Ph.D. from University of Tokyo in 1984. He became Research Associate of Jichi Medical School (1980-82) and University of Tokyo (1984-87). He studied at the Clinical Hematology Branch, NHLBI, NIH, USA as a Fogarty Fellow (1985-87). He became Assistant Professor in 1987 and then Associate Professor in 1990 of The Institute of Medical Science, The University of Tokyo (IMSUT). In 1994 he became Professor of the Institute of Hematology, Jichi Medical School. He was Professor and Chairman of the Division of Hematology, Department of Medicine (1998-2014) and Professor of the Division of Genetic Therapeutics, Center for Molecular Medicine (1998-2014), Jichi Medical University. He was Director of Center for Molecular Medicine (2008-14). He was also Professor of the Division of Immuno-Gene & Cell Therapy (Takara Bio), Jichi Medical University (2011-14). He became Director of IMSUT Hospital and Professor of the Division of Genetic Therapeutics, The Advanced Clinical Research Center, IMSUT (2014-18). He was also Director of Center for Gene & Cell Therapy (CGCT), IMSUT (2014-18). In 2018, he became Professor Emeritus and Visiting Professor of the Division of Immuno-Gene & Cell Therapy (Takara Bio), Jichi Medical University. He is also Senior Adviser of the Center for Gene Therapy Research (CGTR), Jichi Medical University (2018- ). In 2021, he became Independent Director of TERUMO Corporation. Dr. Ozawa has authored 480 original scientific and medical articles and 62 reviews and book chapters.
Head of Department, Royal Prince Alfred Hospital/Sydney Local Health District
John E. J. RASKO AO
BSc (Med), MBBS (Hons), PhD, MAICD, FFSc(RCPA), FRCPA, FRACP, FAAHMS
Professor John Rasko is an Australian pioneer in the application of adult stem cells and genetic therapy. Since 1999 he has di-rected the Department of Cell & Molecular Therapies at Royal Prince Alfred Hospital and the Gene and Stem Cell Therapy Pro-gram at the Centenary Institute, University of Sydney.
He is a clinical haematologist, pathologist and scientist with an international reputation in gene and stem cell therapy, experi-mental haematology and molecular biology. In over 200 publica-tions he has contributed to the understanding of stem cells and blood cell development, gene therapy technologies, cancer cau-sation and treatment, human genetic diseases and molecular biology.
He serves on Hospital, state and national bodies including Chair of GTTAC (OGTR) and past Chair of the TGA Advisory Committee on Biologicals. He co-founded and was past-President of the Australasian Gene & Cell Therapy Society and has served as President, President-Elect, and Vice President of ISCT.
Invited Speaker (appear in sessions order)
Principal Investigator, Gene Transfer Laboratory, University of Otago
Alex McLellan obtained his doctoral training in haematology at the University of Otago (PhD awarded 1997). He then undertook post-doctoral training at the University of Würzburg on murine models of dendritic cells and antigen presentation. His current projects at the University of Otago involve artificial antigen presenting cells for NK cell expansion, bi-directional and inducible promotor systems to improve T cell and NK cell activity and life-span.
Attending Physician National Taiwan University Hospital
Dr. Ming YAO got his M.D. degree from National Taiwan University (NTU) in 1988. He received residency of internal medicine and hematology fellow training from 1990 to 1995 at NTU hospital (NTUH). He became attending physician of division of hematology in department of internal medicine at NTUH since 1995. He studied at Europe as a research scientist at Saint-Antoine Hospital, University Paris VI, France from 1995 to 1997. He was president of Taiwan Blood and Marrow Transplantation (TBMT) Society from 2016 to 2019. He is now the director of BMT unit and cell therapy center at NTUH.
Professor, National Yang Ming Chiao Tung University
Research Fellow & Deputy Director, Institute of Cellular and Organismic Biology
Dr. Kuo is a well-recognized stem cell biologist in Taiwan and internationally. He received his Ph. D. in reproductive medicine from King’s college London, UK in 2001 and did additional postdoctoral training in pluripotent stem cell biology from the prestigious primate cloning laboratory at National Oregon National Primate Research Center (ONPRC) under Dr. Don Wolf ‘s mentorship. Dr. Kuo is well trained in molecular embryology and stem cell biology. In 2003, Dr. Kuo was recruited by Dr. Lee Yuan Tseh, Nobel Laureate and former President of Academia Sinica to join the newly establish Stem Cell Program of GRC/ICOB. At this stage, his primary effort is to help the program to establish the pluripotent stem cell research platform. Since taking his position as an Associated Research Fellow at ICOB in 2013, his primary research focus on exploring the functional role of non-colinear (PtNcl) RNAs in human pluripotency maintenance, reprogramming and human diseases. He was promoted to Full research Fellow in 2018 and took the deputy directorship of ICOB in 2019. His works contribute greatly to our understanding of the function and regulatory pathways of the trans-spliced and circular RNAs underlining pluripotency maintenance, reprogramming and human diseases.
Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Dr. Yee is a Professor in the Division of Cancer Medicine, Director of Solid Tumor Cell Therapy, Director of the Program in TCR-based Therapeutics and Co-Director of the Adoptive Cellular Therapy Platform at UT MD Anderson Cancer Center. He received his medical training in Canada, residency at Stanford and fellowship at Fred Hutchinson Cancer Research Center. He is an elected member of the American Society of Clinical Investigators, CPRIT Clinical Investigator, co-Leader of the Stand Up to Cancer- AACR/CRI Dream Team and recipient of translational scientist awards from Burroughs Wellcome Fund, Damon Runyon Cancer Research Foundation, and the Rao Potul Basic Science Award. He holds an endowed position as the Kenneth Muller Professorship of Melanoma Research. Over the last 20+ years, Dr. Yee has pioneered a form of ACT, known as Endogenous T Cell (ETC) therapy, using peripheral blood to generate a uniform population of antigen-specific memory T cells. He has conceived and executed several IND-approved first-in-human clinical studies establishing principles of T cell persistence, memory and antigen-spreading as fundamental to the success of adoptive cell therapy in a modality known as Endogenous T Cell (ETC) therapy, including the first-in-class use of tetramer-guided cell sorting to generate memory T cells and the first prospective trial using ETC in combination with immune checkpoint therapy. He is corresponding or lead author in > 80 publications, including The New England Journal of Medicine, Nature, Science, Science Immunology, Science Translational Medicine, Nature Medicine, Journal of Clinical Oncology, Journal of Experimental Medicine, Gastroenterology and Cancer Immunology Research. He holds > 15 worldwide inventions on ex vivo generation of antigen specific T cells, memory reprogramming, and antigen discovery and seeks to extend immunotherapy-based cancer treatments globally. His work converges multidisciplinary and collaborative approaches in bioengineering, metabolism, molecular immunology and cellular biology to develop effective immunotherapy strategies and adoptive cellular therapy, in particular, as a treatment modality for patients with malignant diseases.
Hospital Professor The Institute of Medical Science, The University of Tokyo
Nagamura MD, PhD is a physician scientist engaging with the study of umbilical cord tissue-derived mesenchymal stromal cells (UC-MSC) and clinical potential. Her major is hematology and cell processing, especially somatic stem cell research including hematopoietic stem cells and mesenchymal stromal cells (MSC). After she worked in Tokyo cord blood bank as quality manager, she established umbilical cord blood and UC-MSC bank, namely IMSUT CORD to serve the UC-MSCS for clinical and research use, off-the-shelf. She also instructed the graduate students and collaborates with several companies to study UC-MSC for cerebral palsy and other inflammatory diseases. She led the Investigator’s-initiated clinical trial using UC-MSC for severe acute graft-versus-host disease from 2018-2020. IMSUT CORD manufactured and shipped UC-MSC for cerebral palsy and COVID-19-related ARDS in 2021. She continues to explore the possibility of UC-MSC for clinical applications by proving scientific efficiency.
Research Fellow, Institute of Molecular Biology, Academia Sinica
My entry into the field of immunology started in postdoctoral training through working on T cell and natural killer (NK) cell development. We studied the role of MHC class I molecule (MHC-I) in target recognition and education of NK cells, and found that the engagement of MHC-I by NK cell during development is essential for the acquisition of NK cell function. Being a principal investigator at Institute of Molecular Biology, Academia Sinica, I first studied intestinal intraepithelial lymphocytes (iIELs). We found that CD8+ iIELs respond much better to T cell receptor stimulation in the presence of interleukin 15 (IL-15) compared to IL-2, which led our research focus to investigating the function of the IL-15 system. We generated several genetically manipulated mouse models to study the function of IL-15 expressed by different cell types in different tissues under physiological and pathological conditions. We found that IL-15 is a survival factor for NK cell, iNKT cell, conventional CD8+ T cell, and CD8+ iIELs. Moreover, different NK cell developmental events require different levels of IL-15 trans-presentation. In addition, IL-15 expressed by thymic antigen presenting cells negatively regulates autoimmunity through affecting T cell development in the thymus. Under inflammatory conditions, skeletal muscle cell IL-15 and brain IL-15 exacerbate autoimmune myositis and brain injury induced by ischemia stroke, respectively, through activation of T and NK cells. Recently, we have focused on the development of effective combination immunotherapy for metastatic cancer using NK cell and clinically approved chemical drugs.
Associate Investigator and Attending Physician, National Institute of Cancer Research, National Health Research Institutes
Dr. Kwang-Yu Chang was graduated from Kaohsiung Medical University for the Medical Degree in 2012. He received resident training for internal medicine, oncology, and hematology in National Cheng-Kung University Hospital, Tainan, Taiwan, between 2012 to 2007. He started his research career in National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan, and was promoted as Associate Investigator and Attending Physician in 2019. Dr. Chang conducts early phase clinical trials and translational researches. His research interest in medical science is cancer immunology, cancer biology, and drug development.
Assistant Professor Far Eastern Memorial Hospital
Dr. Ho is a corneal specialist in the Department of Ophthalmology, Far Eastern Memorial Hospital, New Taipei City, Taiwan. In the area of service, he is specialized in corneal transplantation, diagnosis and treatment of corneal and ocular surface diseases. In the area of research, his interest lies in studying corneal endothelial cell biology, corneal endothelial regeneration and diagnosis of dry eye disease.
Associate Professor, Department of Biological Science and Technology, China Medical University
Currently, I am an associate professor in China Medical University. I graduated with a Ph.D. degree from Department of Biomedical Imaging and Radiological Sciences. I have been trained in Tu & Yuen Center for Functional Onco-Imaging, School of Medicine, University of California Irvine, Ir-vine, CA, USA by short-term ex-change program. The major research in our group is focus on using theranostic probe, gene engineered mesenchymal stem cells (GE-MSCs) and molecular images to apply on oncology and immunology field. Cell-based therapy system is a “Living Drugs” system, which display better potential to fight cancer. Due to tropism to the tumor microenvironment, MSCs can be considered as promising vectors for the delivery of antitumor agents. Fabricate MSCs based gene delivery system may be used as a promising anti-tumor agent, which could provide a new benefit for cancer patients. Our group is the first group that successfully developed a dual gene modified umbilical cord derived MSCs for lung cancer and brain tumor treatment. We used the advantage of tumor tropism ability of MSCs to precisely delivery dual therapeutic target genes into tumor area to execute effective anti-tumor effect. In this field of development, we received a National Intervention Award in the Business Category in 2021 on GE-MSCs related application. Furthermore, we also collaborated with University of Melbourne to expand the possibility of using reprogramming system to prepare autologous engineered neural stem cells (NSCs) for glioblastoma. The overall GOAL of our research is the provision of new insights into oncology therapeutic approaches and aimed at prolonging the overall patient survival.
Head of Health Research Center, Universitas Trisakti
Dr. Ferry Sandra, Ph.D. obtained his PhD from Kyushu University in 2001. Then he pursued postdoctoral training in Kyushu University and Harvard Medical School. In addition, he took certification in project management. His passion in research has led him being exposed to the following research area: oncology, stem cell biology, signal transduction, herbal medicine, regenerative medicine and medical biotechnology.
During his working career, he served several positions including Chairman of Indonesian Stem Cell Association; Steering Committee of Medical Research Unit of University of Indonesia; Head of Laboratory of Institute of Human Virology and Cancer Biology, Universitas Indonesia; Senior Research Advisor of Kalbe Pharmaceutical Company; Director of Stem Cell and Cancer Institute; Board of Indonesian Biotechnology Consortium.
His current assignments are also numerous, including Head of Expert Board of Indonesian Society for Cancer Chemoprevention; Head of Health Research Center, Universitas Trisakti; Vice President of the Indonesian Association for the Study of Medicinals; Editor in Chief of the Indonesian Journal of Cancer Chemoprevention; Executive Director of The Prodia Education and Research Institute.
In order to develop biomedical science in Indonesia, together with his colleagues, he established some research institutes at both academic and industrial sites. In summary, he gave lectures as an invited speaker at more than 250 seminars, published more than 170 scientific articles/books and supervised more than 30 postgraduate students. In clinical studies, he has more experience as an investigator in regenerative medicine, although some assignments as sponsor and site management were also conducted.
Phu Chi Dung
Phu Chi Dung
Director Blood Transfusion Hematology Hospital, Ho chi minh city
Dr. Phu Chi Dung is in charge of many important positions of Hematology field in Vietnam and international. He is a director of BTH hospital, President of HCMC Blood Transfusion and Hematology Association; Vice President of Asia Cellular Therapy Organization (ACTO), Vice President of Viet Nam Hematology and Blood Transfusion; Vice President of Hereditary Coagulation Disorders Vietnam- Southern Branch. In addition, he is a board member of Stem cell transplant Association- HCMC, Association of Nephrology & Urology, Association of Intensive Care and pediatric Organ Transplant Vietnam, Oncology Association Vietnam.
Dr. Phu Chi Dung has been internship of hematology and Stem cell transplantation at Saint- Antoine Institute, Paris, France from 1998 to 1999; fellowship at department of Hematology and Hematopoietic Stem cell transplantation- Jules Bordet Institute- Belgium in 2004. He completed Philosophy of Medicine degree at Ha Noi University of Medicine in April 2020.
He is one of pioneers contributed to cord blood bank in Vietnam and has conducted many studies published in Vietnam and international sicentific journal.
Moreover, Dr. Phu Chi Dung has also been chairman and speaker at many congress in Vietnam and international, operated and organized successfully many international Congress in Vietnam, such as Vietnamese- French Blood and Transplantation Congresses in 2012, 2014, 2016, 2018; Vietnamese- Belgian on Hematopoiectic Stem cell transplantation Congress in 2012; Asian Pacific Stem cell transplantation Congress in 2013.
Dr. Phu Chi Dung is a lecturer of HCM University of Medicine and Pharmacy, Pham Ngoc Thach University of Medicine, and Head of Hematology Module of Medicine Faculty-HCMC National University. He was granted Professor title from University of Grenoble Alpes- France in April 20th, 2019.
Professor, Pediatric Department, Faculty of Medicine, Ramathibodi Hospital, Mahido University, Thailand
Deputy Director, Clinical Research Centre ACTREC, Tata Memorial Centre
Dr. Navin Khattry
Deputy Director ,Clinical Research Centre
Professor, Dept of Medical Oncology,
ACTREC, Tata Memorial Centre
Calcutta Medical College, Calcutta, India
P.G.I.M.E.R, Chandigarh, India
AIIMS, New Delhi, India
Bristol Royal Hospital for Children, Bristol ,UK.
Research Papers- 77
Chapters in books-6
Area of Special interest
1. Haematopoietic Stem cell Transplantation
Director and Professor, Center for Stem Cell and Regenerative Medicine Tokyo Medical and Dental University
Professor Ichiro Sekiya is a director of Center for Stem Cell and Regenerative Medicine at Tokyo Medical and Dental University, Japan. He completed a specialization in orthope-dics and passed the Japan Orthopedic Association (JOA) Exam in 1996. Ichiro Sekiya’s research has been focused on cartilage and meniscus regeneration with autologous synovial stem cells. He started a clinical study for cartilage regeneration in 2008, which was published in Clin Orthop Relat Res in 2015. He also started another clinical study for meniscus regeneration in 2014, which was published in Cell Transplantation in 2019. Currently he is developing 3D MRI analysis software for knee cartilage and meniscus.
Professor, University of Tsukuba International Center for Materials Nanoarchitectonics (WPI-MANA)
Dr. Mitsuhiro Ebara is a group leader of Smart Polymers Group at National Institute for Materials Science (NIMS). He studied at Waseda University, where he received B.S. (1995), M.S. (1999), and Ph.D. (2004) degrees in the Department of Applied Chemistry. He was a Postdoctoral Fellow at University of Washington from 2004 to 2006. He became an assistant professor at Osaka University Hospital in 2007 and moved to NIMS in 2009. He is also appointed as professors at University of Tsukuba and Tokyo University of Science. He has been also working as a advisor for many companies. Dr. Ebara’s research group focuses on developing smart biotechnologies using stimuli-responsive polymers. He has published over 100 scientific papers and 100 review papers.
Professor, Jeonbuk National University
Dr. Gilson Khang was born in 1960 in South Korea, where he ob-tained his degrees at the Inha Univ. He was studying for Ph.D. de-gree at the Department of Biomedical Engineering, The Univ of Io-wa (Iowa City, IA, USA) from 1991~1995. His academic career started at the Department of PolymerNano Science and Technology at Chonbuk National University (CBNU). Dr. Khang was the one of Founder Members of TERMIS-AP Chapter. Prof. Khang was General Secretary and Treasurer for 2005~2009 of TERMIS-AP Chapter and served as a council member for TERMIS-AP. He was TERMIS-AP Past-President, & Founding Fellow TERMIS. He has co-authored or edited ~30 books. He has published ~700 original research papers, and ~200 editorials, reviews or chapters in books. His papers were cited 16,520 times. (h-index >68) His major scien-tific contribution has been to appreciate and analyze the importance of natural/synthetic hybrid scaffold to reduce the host inflammation reaction as well as the commercialization for tissue engineered products as cartilage, bone, retinal pigment epithelium, cornea endo-thelium, etc. His international collaboration network is really worldwide and tight over 7 countries and 15 Universities. He is/was engaging the Visiting Professor of Tsinghua Univ, Peking Univ, Zhejiang Univ, China and Wake Forest Institute of Regenerative Medicine, USA.
Fernando A. Fierro
Fernando A. Fierro
Associate Adjunct Professor, Stem Cell Program, UC Davis
Stem cell biology and their application in the development of novel cell-based therapies (regenerative medicine). In particular human multipotent stromal cells (MSCs) and skeletal stem/progenitor cells (SSPCs) and their potential to repair damaged tissue by either differentiation or release of paracrine factors.
Publications (Pubmed): 38
Citations (Google Scholar): 2201
h-index (Google Scholar): 25
i10-index (Google Scholar): 31
1996 - 1997: College with mention in natural sciences. University of Chile.
1998 - 2002: Engineering in Molecular Biotechnology. University of Chile.
2002 - 2004: Diploma: Institute for nutrition and food technology (INTA), University of Chile. Graduate as Engineer in Molecular Biotechnology. thesis at JJ Minguell group
• Mentor: Juan José Minguell, PhD
• Projects: Interaction of mesenchymal stem cells and breast cancer cells, Characterization of a subset of Mesenchymal Stem Cells.
• Major techniques: Transmission electron microscopy, cell culture, immunocytochemistry.
2004 - 2008: PhD Student at the International Max Planck Research School (IMPRS) for Molecular Cell Biology and Bioengineering and the University of Technology Dresden.
• Mentor: Gerhard Ehninger, MD.
• Place: Dresden, Germany.
• Project: Induction of drug resistance in leukemic blasts by interaction with mesenchymal stem cells.
• Major techniques: cell culture, flow cytometry, laser scanning confocal microscopy, western blot, PCR
2008: Postdoctoral Training
• Mentor: Martin Bornhauser, MD (part of G. Ehninger’s group).
• Place: Dresden, Germany.
• Project: MicroRNA biology in mesenchymal stem cells.
• Major techniques: microRNA isolation and detection, luciferase assay, in situ hybridisation, transfection for overexpression and silencing of microRNAs in MSC.
2008 – 2012: Postdoctoral Training
• Mentor: Jan Nolta, PhD.
• Place: Institute for Regenerative Cures, UC Davis, Sacramento California.
• Project: Role of autocrine growth factors in mesenchymal stem cells.
• Major techniques: DNA cloning, cell culture, real time-PCR, western blot, flow cytometry.
• Place: Institute for Regenerative Cures, UC Davis, Sacramento California.
• Projects: Scaffolds for Dermal Regeneration with MSC for non-healing ulcers, genetically engineered MSC for critical limb ischemia and osteoarthritis, effect of hypoxia on metabolomics and lipidomics of MSC, FGF-2 signaling in MSC, improvement on Reamer-Irrigator-Aspirator system for major bone defects.
• Major techniques: biochemistry, molecular biology, cell biology, genetic engineering, deep sequencing, and different mouse models of disease.
• Recipient, PhD Fellowship Graduiertenkollegs Deutsche Forschung Gemeinschaft (DGF). Germany 2004-2007.
• Carl Gustav Carus Prize to best scientific PhD thesis at Medical Faculty Technical University Dresden (TUD). Germany 2008.
• Recipient, Postdoctoral Fellowship, California Institute for Regenerative Medicine (CIRM) 2010-2012.
Ika Dewi Ana
Ika Dewi Ana
Vice President, University of Gadjah Mada
Professor, Graduate School of Engineering, Osaka University
Michiya Matsusaki was born in Kagoshima, Japan in 1976. He received his Ph.D. degree in 2003 from Kagoshima University. He started his academic career as a Postdoctoral fellow at Osaka University from 2003. He was a visiting scientist at Lund Univer-sity in 2004. In 2006, he joined the Department of Applied Chemistry in the Graduate School of Engineering at Osaka Uni-versity as an Assistant Professor. He promoted to Associate Pro-fessor in 2015 and to full Professor in 2019. He was a JST-PRESTO researcher (Concurrent position) from 2008 to 2011 and 2015 to 2019. He was awarded 20 awards including Young Scien-tist’s Prize by the Minister of Education, Culture, Sports, Science and Technology. He published 180 papers and his h-index is 42. His research interest is biomaterials and tissue engineering for regenerative medicine and pharmaceutical applications.
Vice President , Department of Orthopedics, Far Eastern Memorial Hospital
Professor Chang studied PhD at the Institute of Biomedical Engineering in National Taiwan University, he was the pioneer in the field of cartilage regeneration in Taiwan. And now professor Chang teaches in Yuan Ze University and is also the vice-president of Far Eastern Memorial Hospital (FEMH).
Professor Chang established the department of orthopedic surgery, made it independent from the Department of Surgery in FEMH. He also devoted to education of orthopaedic residents. Professor Chang have numbers of inventions and publications, and got the National Innovation Award twice, Yuan Ze Outstanding Professor of Hsu Scientific Award, FEMH Outstanding Researcher, Platinum Awards of Taipei Int’l Invention Show & Technomart, Educational Research Award of 3rd New Taipei Medical Charity Award and 2020 Far Eastern Spirit Award.
Professor Chang was the president of Formosa Association Regenerative Medicine (FARM). Since the Specific Medical Management Regulation started by the Taiwan government, FARM had discussed a compulsory training course of the regulation with Taiwan Association for Cellular Therapy and Taiwan Society for Stem Cell Research. The three societies had significant contribution to the government policies of regenerative medicine and cell therapy in Taiwan.
B. Linju Yen
B. Linju Yen
Deputy Director, Regenerative Medicine Research Group, Institute of Cellular & System Medicine, National Health Research Institutes (NHRI)
Our research centers around finding easily accessible sources of human mesenchymal stem cells (MSCs)—such as from ethically compliant term placenta and pluripotent stem cells, including both human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs)—for therapeutic application. MSCs are multipotent somatic stem/progenitor cells with immunomodulatory properties towards diverse leukocyte populations. The strong immunomodulation of MSCs allow for use of these versatile progenitors in regenerative medicine as well as immune/inflammatory diseases. Moreover, these properties also allow for unmatched allogeneic use, thereby expanding the clinical use of MSCs as readily available, “off-the-shelf” products. Our lab has special interest in elucidating molecular mechanisms involved in tissue-specific MSC immunomodulation to improve targeting towards specific clinical indications, as well as MSC tissue engineering for regenerative medicine.
Raymond Ching Bong Wong
Raymond Ching Bong Wong
Principal Investigator, Centre for Eye Research Australia, University of Melbourne
Associate Professor Raymond Wong is a Principal Investiga-tor at the Centre for Eye Research Australia (CERA), the Uni-versity of Melbourne and a Guest Professor at Shenzhen Eye Hospital (China). He is a stem cell biologist with >19 years of research experience, specialising in cellular reprogramming and stem cells in eye research. He completed his PhD in stem cell biology at Monash University and was awarded a Califor-nia Institute of Regenerative Medicine Fellowship to pursue overseas postdoctoral training at the University of California Irvine (USA), and a Visiting Fellow Award to train at the Na-tional Institutes of Health (USA). In 2013, A/Prof Wong joined CERA with the support of a Cranborne Foundation Fellowship and subsequently established the Cellular Reprogramming Unit with the support of a MAWA Fellowship and a New In-vestigator Grant from the National Health and Medical Re-search Council in Australia. Currently, A/Prof Wong’s re-search focuses on understanding the genetic signals that de-fine retinal cells, and using cell reprogramming and stem cell technologies to study and treat retinal degenerative diseases.
Sung-Jan (Jerry) Lin
Sung-Jan (Jerry) Lin
Professor, National Taiwan University
Dr. Sung-Jan Lin is the Taiwan Bio-development Foundation (TBF) Chair in Biotechnology and Professor of Institute of Biomedical Engineering and the Director of Research Center for Developmental Biology and Regenerative Medicine at National Taiwan University. He is also a dermatologist in National Taiwan University Hospital. He received his MD and PhD from College of Medicine and College of Engineering in National Taiwan University. He takes hair follicles, a miniorgan with distinct structures and growth cycles, as a model to understand how a complex organ and its resident stem cells interact with the environment and respond to various insults to decipher the principles and machinery of tissue regeneration. His lab employs a multidisciplinary approach by combing the knowledge learned in biology and tissue engineering to mitigate organ damage and to enhance tissue regeneration. He has published ~150 journal papers in associated journals, including Cell, Science, PNAS, Nature Communications, Biomaterials, Optics Letters, etc. His work has been recognized by Award for Junior Research Investigators in Life Science of Academia Sinica, Physician Scientist Award of Taiwan National Health Research Institutes, Distinguished Research Award of Taiwan Ministry of Science and Technology and Outstanding Professor Award of Far Eastern Y.Z. Hsu Science and Technology Memorial Foundation. In 2014, he was elected as Taiwan Bio-development Foundation (TBF) Chair in Biotechnology. In 2020, he was elected as Kenneth K. Wu Chair Professor. In 2021, he was elected as President of Taiwanese Society for Investigative Dermatology and President of Taiwan Society for Stem Cell Research
Vice President and General Director, Industrial Technology Research Institute
Vice President, Office of Research and Development, National Tsing Hua University
CEO, LuminX Biotech Co., Ltd Job Title
Dr. Long-Jyun Su spin off LuminX Biotech from Academia Sinica, and
developed『LuminX Cell Tracking Enabling Platform』 to assist the
technological development of the global bio-industry, targeting the
needs in cell therapy/regeneration medicine, cancer/tumor metastasis,
immunotherapy. His goal is to shorten the client’s R&D time,
and help them better understand the biological outcome of cells before
conducting clinical trials.
• Ph.D., Department of Chemistry, National Taiwan University
• LuminX Biotech Co., Ltd. CEO/Co-Founder.
• Hsinchu Science Industrial Park, FITI program consultant.
• BioDiamond biotechnology Co., Ltd, CTO/Co-Founder
• Institute of Atomic and Molecular Sciences, Academia Sinica,
• 2022 Economic Daily News Start-up Star winning team
• 2022 TAcc+ Batch#7 DemoDay International development prize
• 2022 Taiwan Start-up World Cup-First Runner Up
• 18th National Innovation Award Start-up Enterprise Award
• 17th National Innovation Award Start-up Enterprise Award
• 16th National Innovation Award Start-up Enterprise Award
• 2021 COMPUTEX d&i Awards-Startup Award
• 2021 NBRP Demo Day - Industry Pioneer Gold Award
• 2019 Academia Sinica-Core Facilities and New Instrumentation
• 2015 MOST- FITI Program - Entrepreneurship Excellence Award
• 2015 The Winter School of Sokendai/Asian CORE Program
Distinguished Professor, Department of Physiology, Orthopaedic Research Center
Distinguished Professor, Department of Physiology, Orthopaedic Research Center
CEO, Regenerative Medicine and Cell Therapy Center, Kaohsiung Medical University
Special Issue Editors, Biomedicines-Special Issue "Regenerative Medicine for Bone and Cartilage and Pathophysiology of Degenerative Diseases"
The 9th Executive Director, Formosa Association Regenerative Medicine
Executive Director, Taiwan Orthopedic Research Society
Regenerative Medicine Advisory Panel Member, Taiwan Food and Drug Administration
Regenerative Medicine and Cell Therapy Developing Advisory Panel Member, Ministry of Health and Welfare
Committee, the 21st FJMD editorial committee, Taiwan Orthpaedic Association
Committee, The Kaohsiung Journal of Medical Sciences
1993.09-1999.06 Ph.D., Graduate Institute of Medicine, Kaohsiung Medical College
1983.09-1986.06 M.S., Graduate Institute of Medicine, Kaohsiung Medical College
1973.09-1977.06 B.S., School of Pharmacy, Kaohsiung Medical College
2020.08-2021.08 Associate Dean, College of Medicine, Kaohsiung Medical University
2019.08-present Executive Director, Regenerative Medicine and Cell Therapy Research Center (RCC),
Kaohsiung Medical University
2019-08-present Distinguished Professor, Department of Physiology/ Orthopaedic Research Center,
Kaohsiung Medical University
2017-2020 Chairperson of medical device domain, Southern Taiwan Interdisciplinary Center for
2001.11-2018.07 Director, Orthopaedic Research Center, Kaohsiung Medical University
2008.02-present Professor, Department of Physiology, Kaohsiung Medical University
2015.08-2018.07 Dean, Office for Operation of Industry and University Cooperation, Kaohsiung
2006.08-2015.07 Chair, Department of Physiology, Kaohsiung Medical University
1996.08-2007.01 Associate Professor, Department of Physiology, Kaohsiung Medical University
1992.02-1993.01 Research Fellow, Department of Orthopaedics, University of Virginia, USA
1986.08-1996.07 Instructor, Department of Physiology, Kaohsiung Medical College
Bone cell biology, Physiology, Pharmacology, Stem cell/ Regenerative medicine
9th Outstanding Alumnae of Kaohsiung Medical University School of Pharmacy (2019)
Ministry of Science and Technology Academic Research Award (2018)
Ministry of Education Outstanding Faculty Teaching Award (2018)
National Innovation Award (2011, 2016, 2017) / Institute for Biotechnology and Medicine Industry, Taiwan
The Prize of Excellent Thesis Competition (2010, 2011, 2013, 2014) / Taiwan Orthopaedic Research Society
The Second Prize of Oral Presentation (2002) / Taiwan Orthopaedic Association
CEO, ILIAS Biologics, Inc.
Dr. Choi is the founder of ILIAS Biologics, Inc. and a pioneer in exosome-based protein drug delivery systems. As a professor at the Korea Advanced Institute of Science and Technology (KAIST), Dr. Choi has published over 130 papers in major scientific journals and obtained over 30 international patents. He established the exosome-based platform technology for protein drug delivery which became the foundation of ILIAS Biologics. He also developed the world’s first medical imaging device for diabetic peripheral vascular disease.
Dr. Choi earned his M.D. in Medicine and Ph.D. in Microbiology from Yonsei University, College of Medicine.
Hsin Hsin Shen
Hsin Hsin Shen
Deputy General Director, Industrial Technology Research Institute
Education/Training: Ph.D. Genetics, National Yang-Ming Uni-versity, Taiwan
Professional and Research Experience:
• Division Director of Division of Regeneration Medicine Technology, Biomedical Technology and Device Research Laboratories , ITRI (2017 to Present)
• Deputy Chief Operating Officer of Center of Excellence for Combination Products, Biomedical Technology and Device Research Laboratories, ITRI (2014-2016)
• Division Director of Division of Tissue Regeneration Prod-uct Technology, Biomedical Technology and Device Re-search Laboratories, ITRI (2012-2014)
• Deputy Division Director of Division of Tissue Regeneration Product Technology, Biomedical Technology and Device Re-search Laboratories, ITRI (2010-2011)
• Research Supervisor of Division of Combination Products, Biomedical Technology and Device Research Laboratories, ITRI (2008-2009)
• Manager of Department of Cell Engineering Technology, Stem Cell and Cell Therapy Program, Biomedical Engineer-ing Research Laboratory , ITRI (2006-2007)
• Manager of Department of Neural Tissue Engineering Pro-gram, Division of Biomaterials and Tissue Engineering, Bio-medical Engineering center, ITRI (2002-2005)
• Researcher, Division of Biomaterials and Tissue Engineer-ing, Biomedical Engineering center , ITRI (2001-2002)
Awards and Honors:
• The silver winner for the 2022 Edison Awards™
• The winner for the 2021 R&D 100 Awards
• Certificate of the National Innovation Award , Institute for Biotechnology and Medicine Industry , Taiwan (2013, 2017, 2019, 2020, 2021)
• First Place, Annual Invention Award, ITRI, Taiwan (2019)
• Outstanding Research Award, ITRI, Taiwan (2018, 2019)
Director, Dept. of Research, Mackay Children's Hospital, Taipei Affiliated Prof., National Yang Ming Chiao-Tung University, and National Defense Medical Center
Chief Professor, Yamaguchi University Graduate School of Medicine
May/1999-March/2001: Resident in Yamaguchi University Hospi-tal
April/2001-March/2005: Graduate Student in Yamaguchi Univer-sity School of Medicine
March/2005-March/2007: Visiting fellow in Laboratory of Exper-imental Carcinogenesis (Laboratory Chief; Snorri S. Thorgeirsson, M.D., Ph.D.), NCI, NIH, USA
April/2008-March/2009: Clinical doctor, Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine
April/2009-March/2012: Assistant professor, Division of Laborato-ry, Yamauchi University Hospital
April/2012-March/2019: Lecture, Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine
April/2019-March/2020: Lecture, Department of Liver regenera-tive medicine (endowed chair by Shibuya Corporation), Yamaguchi University Graduate School of Medicine
April/2020-June/2021: Associate professor, Department of Gas-troenterology and Hepatology, Yamaguchi University Graduate School of Medicine
July/2021-Present: Chief Professor, Department of Gastroenterol-ogy and Hepatology, Yamaguchi University Graduate School of Medicine
Director-General, Taiwan Food and Drug Administration, Ministry of Health and Welfare
Dr. Wu has been the Director-General of the Taiwan Food and Drug Administration (TFDA) since February 2017. Under Dr. Wu’s leader- ship, TFDA have made best efforts overcoming great challenges to ensure the safety, efficacy, and quality of food, medicinal products, medical devices and cosmetics.
Dr. Wu promotes international cooperation, including promoting regulatory harmonization, joint review and sharing TFDA experi- ences in review and regulation with different countries.Recently, Dr. Wu participated in several international meetings such as DIA, ICH, APEC LSIF Policy Dialogue, and Joint Conference of Taiwan and Japan on Medical Products Regulation. Under Dr. Wu’s leadership, TFDA has been serving as the co-champion of APEC Good Registra- tion Management (GRM) Roadmap with Japan MHLW/PMDA, was endorsed as an APEC Training Center of Excellence (CoE) in GRM in 2017 and CoE in Medical Devices in 2020. In addition, TFDA became a regulatory member of ICH in 2018. These international activities significantly foster exchanges and cooperation between TFDA and different regulatory authorities in the world.
Project Associate Professor, Osaka University Graduate School of Medicine
While engaged in medical care as an orthopedic surgeon, he completed the doctoral course at the Graduate School of Medicine, Osaka University and progress the research on pe- ripheral nerve regeneration. He has been seconded to the Ministry of Health, Labor and Welfare since 2011 and worked as a PMDA specially appointed expert from 2012 to 2016. As of 2022, he is a project associate professor of the Osaka Uni- versity Graduate School of Medicine, Strategic Grobal Part- nership & Cross-Innovation initiative, promoting industry-aca- demia collaboration activities especially related to regenera- tive medicine.
Kellathur N. Srinivasan
Kellathur N. Srinivasan
Director, Advanced Therapy Products Branch/ Medicinal Products Pre-market Cluster | Health Products Regulation Group
After completing MSc and MPhil in Biochemistry, Annamalai Uni-versity, I pursued PhD from National University of Singapore (NUS) and post-doctoral research fellowship from the Johns Hopkins Uni-versity School of Medicine and Johns Hopkins Medicine, Singapore. I am currently Director, Advanced Therapy Products Branch at Health Sciences Authority (HSA), Singapore’s National Drug Regu-lator, where I oversee formulation of policies, regulation and guide-lines for cell, tissue and gene therapy products, and authorization of products for commercial supply. I also hold adjunct faculty posi-tion at the Duke-NUS Medical School’s Centre of Regulatory Excel-lence, where I provide inputs to centre’s training curriculum for ad-vanced therapy products. I am the co-lead for the regulatory con-vergence initiatives, together with the United States Food and Drug Administration, to promote and advance prospective regulatory convergence for advanced therapy products under the auspices of Asia Pacific Economic Cooperation (APEC) regulatory harmoniza-tion steering committee. I am also the core member of National Cell and Gene Therapy Work Group of National Research Founda-tion under Prime Minister’s Office, Singapore.
Deputy Review Director, Office of Cellular and Tissue-based Products, PMDA
- 2019-present Deputy Review Director, Office of Cellular and Tissue-based Products, Pharmaceuticals and Medical Devices Agency(PMDA)
- 2015-2019 Senior Reviewer, Office of pharmacovigilance II, Pharmaceuticals and Medical Devices Agency(PMDA)
- 2013-2015 Section chief, blood safety section, Blood and Blood products Division, Ministry of Health, Labour and Welfare(MHLW)
- 2011-2013 Reviewer, Office of Medical Devices, Pharmaceuticals and Medical Devices Agency(PMDA)
- 2009-2011 Reviewer, Office of Biologics II, Pharmaceuticals and Medical Devices Agency(PMDA)
- 2009 Ph.D. in Science, Graduate School of Life and Environmental Sciences, University of Tsukuba
Maria Cristina Galli
Maria Cristina Galli
Istituto Superiore di sanità (ret.)
Dr. Galli holds a University degree in Biological Sciences and a PhD in Molecular Medicine. Her main expertise is in regulatory sci-ences for translational medicine supported by scientific education and research experience in experimental oncology, cellular biology, molecular immunology.
Dr. Galli was active for more than 25 years as basic researcher in experimental oncology, cellular biology, molecular immunology, with most publications on international journals.
Dr.Galli was active for 25 yrs in the field of translational medicine as quality assessor for gene therapy and biotechnology medicines in national as well as in European procedures.
Dr.Galli was active for 25 yrs as GMP and GLP inspector, with special experience in ATMP production and preclinical studies.
Dr. Galli was member of CAT/EMA in 2009-2011 representing Ita-ly.
Dr Galli was vice-chair and then chair of EMA Gene Therapy Working Party in 2008-2012, in which she participated since its first meeting in 2002 and where she was rapporteur of many GTWP guidelines.
After having been co-chair for 3 years, dr. Galli was chair of the ATMP platform in EATRIS-ERIC, the European infrastructure for translational medicine, from 2016 until end 2020
Dr Galli served as chair of the Gene Therapy Product (GTP) work-ing party at the European Pharmacopoeia, EDQM, Strasbourg from 2018 until end 2020.
After having worked there for 30 yrs, in 2020 Dr. Galli retired from Istituto Superiore di Sanità, Roma, Italy.
Annette von Drygalski
Annette von Drygalski
Director, Hemophilia and Thrombosis Treatment Center, University of California San Diego
Annette von Drygalski is a Professor of Clinical Medicine in the Division of Hematology/Oncology, and Director of the Hemophilia and Thrombosis Treatment Center, Department of Medicine, at the University of California, San Diego.
Dr von Drygalski earned her pharmaceutical and medical degrees from the Ludwig Maximilians University, Munich, Germany. She completed residency in Internal Medicine at the Medical College of Wisconsin, Milwaukee, and fellowship in Hematology and Oncology at the University of California, San Diego and The Scripps Research Institute.
Dr. von Drygalski is dedicated to the care of patients with hemophilia and other bleeding disorders addressing the evolving needs of aging patients with hemophilia, such as new therapies, cardiovascular disease and hypertension as well as the progression of hemophilic joint disease. In this role, Dr. von Drygalski investigates gene therapy and other novel molecules in clinical trials, and elucidates effects of new treatments on the pathobiology of joint health, both at the bench and in translational studies. Dr. von Drygalski has pioneered musculoskeletal ultrasound for rapid joint bleed detection and joint evaluation in hemophilia. She is certified in musculoskeletal ultrasound by the American Registry for Diagnostic Medical Sonography, and has developed the Joint Activity and Damage Exam (JADE), a validated ultrasound protocol to quantify synovial and osteochondral changes as well as inflammation in the hemophilic joint. She is also the Director of the CME-accredited course “Musculoskeletal Ultrasound in Hemophilia” at the University of California San Diego.
Dr. von Drygalski also developed a focus in international outreach to afford training for hematologists from developing countries and establish care for patients with hemophilia and bleeding disorders in Mozambique, as well as address mortality from post-partum bleeding.
Head, Division of Translational Oncology, University Hospital Tubingen, Germany
Education and positions
MD, Hannover Medical School, 2000. PhD, Hannover Medical School, 2003. Clinical Resident, Dept. of Pediatric Hematology and Oncology, Hannover Medical School, 2002-2006. Postdoctoral Fellow,
Dept. of Pediatric Hematology and Oncology, Hannover Medical School, 2004-2006. Research Group Leader, Dept. of Molecular Hematopoiesis, Hannover Medical School, 2006-2010. Assistant Professor of ‘Experimental Hematology‘, Dept. of Molecular Hematopoiesis, Hannover Medical School, 2010-2014. Offer, Full-time Faculty as Assistant Professor of Pediatric Hematology and Oncology, Weill Cornell Medical Center, Department of Pediatrics, New York, USA, 2010. Offer, Full Professor of ‘Stem Cells and Aging’, Ulm University, 2012. Offer, Full Professor of ‘Molecular Hematopoiesis’, Hannover Medical School, 2012. Full Professor of “Translational Oncology”, Dept. of Hematology, Oncology, and Clinical Immunology, University Hospital Tuebingen, since 2014.
Clicinal and academic responsibilities relevant to the proposal
Head Reference Laboratory for Research, Diagnostics and Biobanking of the European Branch of the Severe Chronic Neutropenia International Registry (SCNIR), since 2006. Since 2019 Board member, EU-funded Cooperation in Science and Technology (COST) Action “CA18233: European Network for Innovative Diagnosis and treatment of Chronic Neutropenias, EuNet-INNOCHRON”, since 2019. Advisory Board Member, SCNIR, since 2018. Research Group Leader, Dept. of Molecular Hematopoiesis, Hannover Medical School, Hannover, Germany, 2006 – 2010. Medical training in pediatrics, Hannover Medical School, 2002 – 2006.
Research activity relevant to the proposal
Main research interests include the understanding of the molecular pathomechanisms of severe congenital neutropenia and leukemia; establishment of the experimental in vitro and in vivo models of neutropenia, pre-leukemia and leukemia; identification of novel therapeutic approaches for neutropenia, pre-leukemia and leukemia; gene therapy of neutropenia; genetic diagnostics of neutropenia.
Adjunct Professor Dept. of Health Industry, SookMyung Women’s University
Nov 2021 11th ACTO (Asian Cell Therapy Organisation) annual meeting, Hochimin, Vietnam
The clinical preparation of cell therapy products for peripheral neuropathy
Aug 2019 24th Annual Congress of APBMT/ KSBMT,
Current Review of Immunocellular Therapy against Cancer
Nov 2017 2nd Open Scientific Meeting, Breakthrough on Stem cell treatment in Regenerative Medicine, Jakarta, Indonesia
The development and Regulation of Cell Therapy Products in Korea
Natural Killer Cells: Key Factor for balancing the immune system
Manager, Minaris Regenerative Medicin Co., Ltd
I went to Middle and High School in United States. I have a bachelor's degree of chemistry/biology at Kwansei Gakuin Unicersity and master’s degree(MBA) at Nihon Uni-versity in Japan. I have been woking at 3M over 10 years in Pharmaceutical industry as Business Development. I joined this company in 2017 as Business Development when it was “Hitachi Chemical” and just after it launched new busi-ness, Regenerative Medicine. Now, lifescience science section has spinned off and named as “Mi-naris Regenerative nerative Medicine."
COO, Taiwan Bio Therapeutics
Dr. Yang joined Taiwan Bio in 2021 and has been responsible for overseeing Taiwan Bio’s daily business operation, developing R&D strategies and supervising its CDMO services. An accomplished biotech entrepreneur, Dr. Yang funded two biotech startups before joining Taiwan Bio and still serves on their executive boards. Dr. Yang has a DPhil degree in Molecular and Cellular Medicine from the University of Oxford and an MRes degree in Translational Medicine from Imperial College.
Director of Clinical and Business Development, Steminent Biotherapeutics Inc.
Dr. Ho joined SBI in 2012 and leads the Clinical and Business Development.
He is responsible for SBI’s out licensing collaborations
in Japan and Korea and the success of the granted Orphan Drug
Designation of SBI’s cell product, Stemchymal®, for Spinocerebellar
Ataxia treatment in the US and Japan. He has more than 15
years of experience in stem cell science and business development.
Dr. Ho obtained his Ph.D degree in Biomedical Engineering
from University College London, UK.
General Manager, UnicoCell Biomed CO., LTD
Dr. Hung is the General Manager of UnicoCell Biomed. She received her Ph. D. degree in chemical engineering from the university of Birmingham, UK in 2011 and then undertook post-doctoral training at the National Taiwan University Hospital, where she focused on the cancer stem cell 3D culture, cell scaffold and biomaterial research. She has more than 10 years’ experience in stem cell product development from basic research to clinical studies, as well as the management of GTP and PIC/S GMP facility.
CEO/CSO, Acepodia Biotechnologies Limited
Dr. Hsiao is the Chief Executive Officer, President and Co-Founder of Acepodia. He was awarded Dr. Y-T Lee Prize, which named after Nobel Laureate Dr. Lee, for his research achievement in Chemistry. Dr. Hsiao has extensive research experience in immune cell therapy development, which led to the discovery and invention of Acepodia’s novel cellular im-munotherapy development platform, ACC (Antibody-Cell Conjugation). Dr. Hsiao earned his B.S. in Chemistry from Na-tional Taiwan University, and his Ph.D. in Chemistry and Mo-lecular Cell Biology from the University of California, Berkeley.
Project Manager, Gwo Xi Stem Cell Applied Technology Co., Ltd.
Chuck Yang is a project manager for GWOXI Company. The speaker received his PhD in Physiology from National Yang Ming Chiao Tung University. His main research areas are sleep apnea and the mechanism of pulmonary sensory nerves receiving external stimuli. From master to doctoral period, he specialized in animal experiments and was famil-iar with various rat experimental operations. Several SCI papers were accepted and published during his studies. Af-ter graduating from the doctoral program, the speaker en-tered the regenerative medicine industry and is mainly re-sponsible for new drug research and development, includ-ing: stem cell new drug discovery and experimentation, preclinical drug research and development, and clinical trial planning. In the process of new drug development, the speaker has also won a number of national research project funds and won many awards with the department. In addi-tion, the speakers also participated in and assisted in strate-gy formulation, product positioning, technology transfer, market research, cost control, profit evaluation, and cross-departmental coordination and communication. Diverse in-dustry experience enables speakers who are keen to trans-late academic research into clinical applications to advance the new drug development schedule from a comprehensive perspective.
James Chiehliang Lin
James Chiehliang Lin
Associate Vice President, Cell Therapy Department / Medigen Biotechnology Corp.
Experienced R&D director with demonstrated records of executing and coordinating the development of natural killer cell and gamma delta T cell therapeutics, fully human therapeutic antibodies and therapeutic reagents. Skilled in natural killer cell and gamma delta T cell therapy development techniques, recombinant and human antibody isolations, membrane protein purification, virus manipulation and genetic engineering. Established schizophrenic and DCM disease mouse models and pioneered the incorporation of small animal imagining systems such as micro-PET, functional-CT, micro-MRI and Ultrasound and behavioral studies at NTU. Directed a team and mentored with strong communication and social skills. Responsible and results-oriented professional with objectives in alignment with corporate agenda.